No Data
No Data
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and Mediwound (MDWD)
Buy Rating for Mediwound Driven by EscharEx's Market Potential and Disruptive Role in Chronic Wound Care
Citi Initiates MediWound(MDWD.US) With Buy Rating, Announces Target Price $25
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
Mediwound (MDWD) Receives a Buy From TD Cowen
Mediwound Advances in Enzymatic Therapeutics With Strategic Expansions